How much has Blincyto, Corlanor and Imylgic sold?

Discussion in 'Amgen' started by anonymous, Jan 15, 2016 at 4:27 AM.

Tags: Add Tags
  1. anonymous

    anonymous Guest


    r*****, can you read:

    "Patients aren't likely to get two full treatment courses of 28 days apiece, VOI Consulting President Todd Clark told FiercePharma. In clinical trials, the average time on therapy was 21 days for the first cycle and 10 days for the second--and many patients may not need more than one cycle"

    Some three-fourths of patients in trials received a shorter course of therapy than the 56 necessary to hit that $178,000 price tag, the analysis showed--"even in the clinical trial environment where payment was not an issue and patients could be treated for an extended period of time," Clark noted."
     

  2. anonymous

    anonymous Guest

  3. anonymous

    anonymous Guest

    All of us at Amgen knew Onyx was crap!
     
  4. anonymous

    anonymous Guest

    It would be best if they quit and gave us kyprolis. Never so many untalented losers in my life.
     
  5. anonymous

    anonymous Guest

    Jealous much? Test meeting was strange also. Bad culture of us vs them. We are one Amgen. Haha
     
  6. anonymous

    anonymous Guest

    Someone out there must know the sales numbers. They track sales out of distribution center to wholesaler every day. They track wholesaler sales out to pharmacy, clinic, MD office etc. Data from IMS every week. They get wholesaler chargeback data weekly.
    So what has been sold so far. What is this a national secret. Like nuclear codes or KFC secret recipe?
     
  7. anonymous

    anonymous Guest

    The answer is like the punchline to the old joke... What kind of meat does a priest eat?
     
  8. anonymous

    anonymous Guest

    Blincyto has only sold initially when institutions were stocking the product. Right now, it's just sitting on the shelf like a box of used condoms
     
  9. anonymous

    anonymous Guest

    So, these are the results of the "new" pharma executive leadership commercial team launching the new products. Hmmmmmmmmmm.
     
  10. anonymous

    anonymous Guest



    How much has been sold you ask? Well in the words of the famous Dean Wormer of Faber College -
    " zero point zero......"
     
  11. anonymous

    anonymous Guest

    Amgen buys Imyglic and Blincyto for $2B plus development cost of trials and commercialization. Now these products will never sell more than half a billion in their life time.

    Does Amgen understand the time value of money? Come on banker bob. I expect more.
     
  12. anonymous

    anonymous Guest

     
  13. anonymous

    anonymous Guest

    If Amgen still hides these agent under other revenue then we know these products suck
     
  14. anonymous

    anonymous Guest

    News bulletin ....... yes all these new products do indeed suck!

    Captain Obvious
     
  15. anonymous

    anonymous Guest

     
  16. anonymous

    anonymous Guest

    I sell Imlygic and happen to know it is off to a great start.
     
  17. anonymous

    anonymous Guest


    Yes it sucks to have ALL and Blincyto comes around and gets your counts low enough to get to transplant and a durable remission. Real nice dummy supportive care reps...this is called being a biotech oncology company. We will not lose money on Blin, oh and in the meantime we will help people with a deadly disease live longer. Very nice of you to talk shit about that..such professionals we have here. It's talentless jokes like you who help carry on the awful perception that Amgen has in the marketplace. Thanks...
     
  18. anonymous

    anonymous Guest

    CART T is better than Blin! Blin blows ass like your mom!
     
  19. anonymous

    anonymous Guest


    So what CAR-T is approved and available to everyone outside of limited clinical trial sites? You keep proving you are an idiot. Thanks!
     
  20. anonymous

    anonymous Guest

    The reason you can't sell and its lumped with all other underperforming Amgen drug is because docs are putting patients on kite, juno, bluebird bio. Everything besides blin